AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, phase 3 trial for Zoptrex™ (zoptarelin …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today reported …
AEterna Zentaris Inc. (USA) In a research issued yesterday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of AEterna Zentaris Inc.
Canaccord analyst Neil Maruoka expressed a cautious stance today on drug maker AEterna Zentaris Inc. (USA)(NASDAQ:AEZS), after the company reported fourth-quarter financial results that were below …
While new market expansion and acquisitions are expected to play out well, differing revenue structures and supply/demand concerns could have an unfavorable effect …
Biotechnology stocks AEterna Zentaris Inc. (NASDAQ:AEZS) and Horizon Pharma PLC (NASDAQ:HZNP) take the center stage after analysts provide a pipeline update on a drug …
While U.S.
Following the annual J.P.
Canaccord’s healthcare analyst Neil Maruoka weighed in on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after the company announced the finalization of a co-promotion agreement …
